

A Novel Nanoparticle-Coupled MALDI-TOF Approach for High Throughput Low Molecular Weight Biomarker Enrichment, Isolation, Preservation and Discovery


Brian Feild¹, Benjamin Lepene², Claudia Fredolini³, Benjamin H. Espina², Davide Tamburro³, Alessandra Luchini³, Barney Bishop³, Emanuel Petricoin³, Lance Liotta³, Scott Kuzdal¹

¹Shimadzu Scientific Instruments (Columbia, MD), ²CeresNanosciences, LLLP (Manassas, VA)

³Center for Applied Proteomics and Molecular Medicine George Mason University (Manassas VA)


Each year Non Small Cell Lung Carcinoma (NSCLC) claims hundreds of thousands of lives worldwide. Prognosis for this disease is poor requiring a new collection of biomarkers to diagnose and treat patients. Low molecular weight (LMW) and peptidomic information have high potential for providing valuable biomarkers because this information traverses the endothelial barrier from tissue interstitium to circulation. These biomarkers are often masked in mass spectrometric (MS) analysis by highly abundant proteins, requiring intensive sample preparation techniques. A novel nanotechnology reagent, the Nanotrap[®], a core-shell hydrogel nanoparticle, was developed to address many of the issues associated with the analysis of LMW biomarkers^{1, 2, 3}. This presentation focuses on a Nanotrap biomarker discovery platform which combines the Nanotrap's ability to sequester, enrich and protect LMW biomarkers directly from complex biological fluids with the fast, highly sensitive Matrix Assisted Laser Desorption Ionization time of flight mass spectrometry (MALDI-TOF MS) analysis to screen samples for biomarkers. This presentation focuses on the benefits of Nanotrap and how to utilize the Nanotrap platform to identify differences between control and disease serum samples from lung cancer patients.

Nanotrap Sequestration




Core shell hydrogel nanoparticles, or Nanotrap[®]s result from the radical polymerization of N-isopropylacrylamide in the presence of a bait molecule such as acrylic acid or cibacron blue. By controlling the extent of crosslinking, very tight molecular weight cutoffs can be obtained. This results in a single step enrichment strategy that excludes high molecular weight carrier proteins and selectively and non-covalently binds proteins based on the characteristics of the bait. Once harvested directly from complex biological fluids, nanotrap[®]s have the added benefit of protecting biomarkers from protease activity.


The Nanotrap Biomarker Discovery Platform Workflow



Benefits of Nanotrap[®]s for Biomarker Discovery: Sequester, Enrich, Purify and Protect



Non Small Cell Lung Carcinoma Study



Summary

Nanotrap[®]s sequester, enrich, purify and protect LMW biomarkers. This method offers a fast, robust method for screening large sample sets. Its utility was demonstrated in a small scale lung cancer serum study that differentiated sample sets and identified features of interest that would not have been detected without Nanotrap[®] enrichment.

Methods

PDGF sequestration experiment: All reagents purchased through Sigma Aldrich (Saint Louis, MO) unless otherwise noted. 100 μ L of Nanotrap particles (CeresNano, Manassas, VA) were incubated with 1200 μ L of solution containing PDGF-BSA (Cell Signaling Technology, Danver, MA) diluted in 1 mM citrate buffer pH=6, PDGF concentration (600 ng/mL, 60 ng/mL), BSA is present in 10 fold excess. Particles were washed with 1 mL of 18-MQ-cm water twice and eluted with 100 μ L 60% acetonitrile, 2% acetic acid. Eluates (100 μ L) were collected and dried. Samples were digested using: Urea 2 M, DTT 5 mM, Iodoacetamide 15 mM, NH_4HCO_3 100 mM, Trypsin 1:100 (w/w) enzymatic:total protein ratio. Samples were purified with Ziptip pipette tips and dried with a Speed-Vac. The dried samples were reconstituted in 20 μ L 50% ACN, 50% DI H_2O , 0.1% TFA. 0.5 μ L sample was spotted with 0.5 μ L matrix (20 mg / ml Sinapinic Acid in 50% acetonitrile / 50% 18-MQ-cm water) and dried for Matrix Assisted Laser Desorption Time of Flight Mass Spectrometry (MALDI-TOF MS) analysis, MALDI-TOF MS was performed using an AXIMA Performance (Shimadzu, Manchester U.K.) operating in linear positive mode with a 337 nm nitrogen laser firing at 50 Hz.

NSCLC Serum study: Human serum from five NSCLC (non small cell lung cancer) patients and five control individuals (CT scan negative) (150 μ L each) was diluted with 300 μ L Tris HCl and incubated with 300 μ L CB (Cibacron Blue) containing particles. Particles were collected by centrifugation, washed with 300 μ L water and eluted twice with 50 μ L 70% acetonitrile, 10% Ammonium Hydroxide. Eluate from particles was diluted in α -cyano-4-hydroxycinnamic matrix and spotted in triplicate on a steel MALDI target. The samples were analyzed using an AXIMA Performance MALDI TOF-MS (Shimadzu Biotech, Kyoto Japan). Mass range analyzed was 1000-4000 kDa and the instrument was run in reflectron mode (power 75; profiles 100;shots 50; raster mode).